Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms

Journal of Clinical Oncology

Volumn 28, Issue 9, 2010, Pages 1583-1590

  Piva, Roberto ^a   Agnelli, Luca ^a   Pellegrino, Elisa ^a   Todoerti, Katia ^a   Grosso, Valentina ^a   Tamagno, Ilaria ^a   Fornari, Alessandro ^a   Martinoglio, Barbara ^a   Medico, Enzo ^a   Zamò, Alberto ^a   Facchetti, Fabio ^a   Ponzoni, Maurilio ^a   Geissinger, Eva ^a   Rosenwald, Andreas ^a   Müller Hermelink, Hans Konrad ^a   De Wolf Peeters, Christiane ^a   Piccaluga, Pier Paolo ^a   Pileri, Stefano ^a   Neri, Antonino ^a   Inghirami, Giorgio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; COMPLEMENTARY DNA; NUCLEOPLASMIN; SHORT HAIRPIN RNA; STAT3 PROTEIN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LENTIVIRINAE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA; VIRUS PARTICLE; WESTERN BLOTTING; CELL TRANSFORMATION; GENETICS; PERIPHERAL T CELL LYMPHOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL, PERIPHERAL; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77951906200     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.9759     Document Type: Article

References (42)

1. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994 (Pubitemid 24273002)
2. Rizvi MA, Evens AM, Tallman MS, et al: T-cell non-Hodgkin lymphoma. Blood 107:1255-1264, 2006 (Pubitemid 43242357)
3. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Toumors of Haematopoietic and Lymphoid Tissues. Lyon, France, International Agency for Research on Cancer, 2008
4. Morton LM, Wang SS, Devesa SS, et al: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265-276, 2006
5. Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
6. Savage KJ, Harris NL, Vose JM, et al: ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008
7. Fornari A, Piva R, Chiarle R, et al: Anaplastic large cell lymphoma: One or more entities among T-cell lymphoma? Hematol Oncol [epub ahead of print on April 8, 2009]
8. Stein H, Mason DY, Gerdes J, et al: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985 (Pubitemid 15242469)
9. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284, 1994 (Pubitemid 24107549)
10. Chiarle R, Voena C, Ambrogio C, et al: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23, 2008
11. Thompson MA, Stumph J, Henrickson SE, et al: Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 36:494-504, 2005 (Pubitemid 40776002)
12. Trempat P, Villalva C, Xerri L, et al: Gene expression profiling in anaplastic large cell lymphoma and Hodgkin's disease. Leuk Lymphoma 45:2001-2006, 2004
13. Lamant L, de Reynies A, Duplantier MM, et al: Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109:2156-2164, 2007 (Pubitemid 46348218)
14. Piccaluga PP, Agostinelli C, Califano A, et al: Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67:10703-10710, 2007 (Pubitemid 350145896)
15. Salaverria I, Bea S, Lopez-Guillermo A, et al: Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 140:516-526, 2008 (Pubitemid 351230071)
16. Falini B, Pileri S, Zinzani PL, et al: ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 93:2697-2706, 1999 (Pubitemid 29181203)
17. Gascoyne RD, Aoun P, Wu D, et al: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913-3921, 1999 (Pubitemid 29249840)
18. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al: ALK-negative systemic anaplastic large cell lymphoma: Differential diagnostic and prognostic aspects-a review. J Pathol 200:4-15, 2003
19. ten Berge RL, de Bruin PC, Oudejans JJ, et al: ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43:462-469, 2003
20. Piccaluga PP, Agostinelli C, Califano A, et al: Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117:823-834, 2007 (Pubitemid 46348541)
21. Zinzani PL, Dirnhofer S, Sabattini E, et al: Identification of outcome predictors in diffuse large B-cell lymphoma: Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 90:341-347, 2005 (Pubitemid 40388984)
22. Fu L, Medico E: FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data. BMC Bioinformatics 8:3, 2007
23. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868, 1998 (Pubitemid 29003722)
24. Mattioli M, Agnelli L, Fabris S, et al: Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24:2461-2473, 2005 (Pubitemid 40593037)
25. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121, 2001 (Pubitemid 32397092)
26. Tibshirani R, Hastie T, Narasimhan B, et al: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99:6567-6572, 2002 (Pubitemid 34526173)
27. Wiznerowicz M, Trono D: Conditional suppression of cellular genes: Lentivirus vector-mediated drug-inducible RNA interference. J Virol 77:8957-8961, 2003 (Pubitemid 36936105)
28. Chatterjee M, Stuhmer T, Herrmann P, et al: Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 104:3712-3721, 2004 (Pubitemid 39564449)
29. Moffat J, Grueneberg DA, Yang X, et al: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283-1298, 2006
30. Piva R, Chiarle R, Manazza AD, et al: Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 107:689-697, 2006 (Pubitemid 43076395)
31. Piva R, Pellegrino E, Mattioli M, et al: Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 116:3171-3182, 2006 (Pubitemid 44878631)
32. Abruzzo LV, Barron LL, Anderson K, et al: Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. J Mol Diagn 9:546-555, 2007 (Pubitemid 47434122)
33. Chiarle R, Simmons WJ, Cai H, et al: Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623-629, 2005 (Pubitemid 40868302)
34. Zamo A, Chiarle R, Piva R, et al: Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21:1038-1047, 2002 (Pubitemid 34174516)
35. Klein U, Tu Y, Stolovitzky GA, et al: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194:1625-1638, 2001 (Pubitemid 33126813)
36. Quintanilla-Martinez L, Pittaluga S, Miething C, et al: NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. Blood 108:2029-2036, 2006 (Pubitemid 44395017)
37. Jundt F, Raetzel N, Muller C, et al: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas. Blood 106:1801-1807, 2005
38. Chin L, Gray JW: Translating insights from the cancer genome into clinical practice. Nature 452:553-563, 2008 (Pubitemid 351483369)
39. Strausberg RL, Simpson AJ, Old LJ, et al: Oncogenomics and the development of new cancer therapies. Nature 429:469-474, 2004 (Pubitemid 38715142)
40. Sawyers C: Targeted cancer therapy. Nature 432:294-297, 2004
41. van't Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452:564-570, 2008
42. Bonzheim I, Geissinger E, Roth S, et al: Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 104:3358-3360, 2004 (Pubitemid 39507158)